New pill shows promise for HER2 lung cancer in early trial
NCT ID NCT05751018
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 study is testing a daily pill called pyrotinib as a first treatment for people with advanced non-small cell lung cancer that has a specific change in the HER2 gene. The trial will enroll 18 adults who have not had prior treatment for their advanced cancer. Researchers will measure how well the drug shrinks tumors and track any side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Pyrotinib (a targeted cancer pill that blocks HER proteins)
What this could lead to
If it works, this could offer a new first-line targeted treatment option for people with HER2-driven advanced lung cancer.
What could go wrong
This is a small, early-phase trial with only 18 participants and no comparison group, so results may not apply broadly. Side effects from pyrotinib are possible, and the drug may not shrink tumors as hoped.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL-CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Peking Union Medical College
RECRUITINGBeijing, Beijing Municipality, 100000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••